Discover

News & Info

Trade

LongbridgeAI

Quote List Quote List

XUANZHUBIO-B(02575.HK)

Event Tracking

Apr20

Xuanzhu Biological Announces Preliminary Clinical Trial Results for NG-350A

09:04

Apr19

Xuanzhu BioPharma Announces Superior Results for Difluorzan in Phase III Clinical Trial Compared to Crizotinib

10:07

Apr14

Xuanzhu Biopharma's Anellazole Sodium Enteric-Coated Tablets Approved for Phase III Clinical Study

22:37

Apr9

Xuanzhu Bio-B Enters into License and Supply Agreement for Pyloricyclin and Delaroqu

08:38

Mar30

XUANZHUBIO-B released FY2025 Annual Earnings on March 30 (BJT), actual revenue HKD 56.58 M, actual EPS HKD -0.5772

15:00

XUANZHUBIO-B released FY2025 Q3 earnings on March 30 (BJT), actual revenue HKD 18.52 M, actual EPS HKD -0.1535

15:00

Schedules & Filings

Schedules

Filings

Mar30

Earning Release(CST)

FY2025 Q4 Earning Release (HKD) Revenue 18.84 M, Net Income -74.84 M, EPS -0.1562

Oct15

IPO(CST)

Listing Price HKD 11.6

Oct6

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 9.792 M, Net Income -60.7 M, EPS -0.1346

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change

XUANZHUBIO-B(02575.HK)

XUANZHUBIO-B Stock Performance Chart